A critical view on the current use of daptomycin in Spain : The daptomise study
Rodríguez González, Carmen Guadalupe (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
Chamorro de Vega, Esther (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
De la Villa Martínez, Sofía (Hospital General Universitario Gregorio Marañón)
Valerio Minero, Maricela (Universidad Complutense de Madrid)
Gutiérrez Urbón, José María (Complejo Hospitalario Universitario de A Coruña)
Giménez Manzorro, Álvaro (Hospital General Universitario Gregorio Marañón)
Fernández de Gamarra Martínez, Edurne (Institut d'Investigació Biomèdica Sant Pau)
Sacristán, Sara Cobo (Hospital Universitari de Bellvitge)
Bouza Santiago, Emilio (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias)
Herranz Alonso, Ana (Hospital General Universitario Gregorio Marañón)
Muñoz García de Paredes, Patricia (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias)
Sanjurjo Sáez, María (Hospital General Universitario Gregorio Marañón)
Universitat Autònoma de Barcelona

Data:	2023
Resum:	The Study on the Clinical Use of DAPTOMycin in Spain (DAPTOMISE Study) is a national surveillance program of daptomycin use. The objectives of this study are to evaluate the current variability in daptomycin consumption across the different hospitals and the adequacy of therapy, specially focused on underdosing. All adult and pediatric patients who received, at least, one dose of daptomycin in a single week in 98 institutions in Spain were included. The adequacy of daptomycin use was evaluated with respect to the indication, dosage, adjustments after microbiology results, switching to an oral agent and length of treatment. A total of 615 patients received daptomycin during the study week. The prevalence use was 2. 3 patients / 100,000 inhabitants per week, 12. 4 patients / 1000 admissions and 9. 2 Days of Therapy (DOT) / 1000 hospital stays. These rates varied between hospitals: from 0 to 13. 9 patients / 100,000 inhabitants, from 0 to 76. 1 patients / 1000 admissions and from 0 to 49. 4 DOT / 1000 hospital stays. The most frequent infections were bacteremia (31. 6 %) and skin and soft tissue infections (17. 9 %). Microbiological results were available in only 65. 4 % of infections. The most frequent microorganisms were Staphylococcus aureus (192 isolates, of which 87 were resistant to methicillin) and coagulase-negative staphylococci (124 isolates). A total of 136 prescriptions (22. 1 %) were underdosed. Dosages < 8 mg/kg were used for 35. 6 % of endovascular infections and for 26. 2 % of osteoarticular infections. Overall, 57. 2 % of prescriptions were not optimal in, at least, one item. Clinical cure rate was 76. 1% and mortality attributable to the infection 8. 1%. This is the first registry that identifies the prevalence of use of daptomycin in Spain and shows a high variability in the consumption between the different hospitals. Daptomycin underdosing was present in more than 20 % of cases.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Daptomycin ; Effectiveness ; Gram-positive infection ; High-dose ; Spain
Publicat a:	Journal of Infection and Public Health, Vol. 16 Núm. 7 (july 2023) , p. 1115-1122, ISSN 1876-035X

DOI: 10.1016/j.jiph.2023.05.008
PMID: 37220712

8 p, 1.1 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats